Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959404 | 0.86 | LMNA (0.50) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL8527692 | 0.83 | LMNA (0.47) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL17277332 | 0.83 | ACHE (0.46) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL12879301 | 0.81 | KMT2A (0.48) | LMNAACHESMN1; SMN2ALDH1A1MTNR1A | |
| SCHEMBL13791121 | 0.80 | ACHE (0.50) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL13790939 | 0.80 | ACHE (0.50) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL6849655 | 0.80 | ACHE (0.43) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL4665496 | 0.80 | MTNR1A (0.51) | LMNAALDH1A1MTNR1AMTNR1BGAA | |
| SCHEMBL20508719 | 0.79 | ACHE (0.48) | LMNAACHESMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL20076063 | 0.79 | ACHE (0.48) | LMNAACHESMN1; SMN2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590929-A1 | ARYLOXY-ALKYLENE SUBSTITUTED HYDROXYPHENYL HEXYNOIC ACIDS, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012010413-A1 | ARYLOXY-ALKYLENE SUBSTITUTED HYDROXYPHENYL HEXYNOIC ACIDS, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010413-A1 | ARYLOXY-ALKYLENE SUBSTITUTED HYDROXYPHENYL HEXYNOIC ACIDS, METHODS FOR THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENT | SANOFI (FR) | 2012-01-26 | — | — | WO | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | HCAR1, HCAR3, CYP2C9 | LMNA 3353/4885ACHE 2858/4885SMN1; SMN2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.